LS132.1D9 [1D9]細(xì)胞

生長(zhǎng)狀態(tài)： 懸浮生長(zhǎng)

ATCC Number： HB-12549?

是否是腫瘤細(xì)胞： 0

物種來(lái)源： 小鼠

運(yùn)輸方式： 凍存運(yùn)輸

數(shù)量： 大量

**類(lèi)型： IgG2a kappa

Designations: LS132.1D9 [1D9]

LS132.1D9 [1D9]細(xì)胞Depositors: LeukoSite, Inc.

Isotype: IgG2a kappa

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Mus musculus (B cell); Mus musculus (myeloma)

Morphology:

Source: Cell Type: hybridoma:

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material.LS132.1D9 [1D9]細(xì)胞 Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Comments: Animals were immunized with CCR2bDEF3.L1/2 cells derived from the murine pre-B lymphoma cell line, L1/2, transfected with the human CCR2B cDNA coding region. Spleen cells were fused Sp2/0 myeloma cells. The antibody binds to the human CC-chemokine receptor 2 (CCR2).

Propagation: ATCC complete growth medium: Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose and supplemented with 25 mM HEPES, 20 pg/ml mouse recombinant Interleukin-6 (IL-6) and 20% fetal bovine serum

Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Temperature: 37.0°C

Subculturing: Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Do not allow the cell concentration to exceed 1 X 10(6) cells/ml.

Interval: LS132.1D9 [1D9]細(xì)胞Maintain cultures at a cell concentration between 1 X 10(5) and 1 X 10(6) cells/ml.

Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)

Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO

Storage temperature: liquid nitrogen vapor phase

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002

recommended serum:ATCC 30-2020

References: 71858: LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,312,689 dated Nov 6 2001

71859: LaRosa GJ, et al. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,352,832 dated Mar 5 2002

71860: LaRosa GJ. Method of inhibiting leukocyte trafficking by anti-CCR2 amino-terminal domain antibodies. US Patent 6,395,497 dated May 28 2002

71861: LaRosa GJ. Method of inhibiting interaction of cells bearing CCR2 by Anti-CCR2 amino-terminal domain antibodies. US Patent 6,406,865 dated Jun 18 2002

71862: LaRosa GJ. Anti-CCR2 antibodies. US Patent 6,406,694 dated Jun 18 2002

71863: LaRosa GJ. Method of inhibiting cell function associated with CCR2 by anti-CCR2 amino-terminal domain antibodies. US Patent 6,448,021 dated Sep 10 2002

71864: LaRosa GJ. LS132.1D9 [1D9]細(xì)胞Anti-CCR2 antibodies and methods of use therefor. US Patent 6,451,522 dated Sep 17 2002

71865: . Anti-CCR2 antibodies and methods of use therefor. US Patent 6,458,353 dated Oct 1 2002

71866: LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,491,915 dated Dec 10 2002